Genomic medicine must reduce, not compound, health inequities: the case for hauora-enhancing genomic resources for New Zealand.

Precision medicine seeks to draw on data from both individuals and populations across disparate domains to influence and support diagnosis, management and prevention in healthcare at the level of the individual patient and their family/whānau. Central to this initiative is incorporating the effects of the inherent variation that lies within genomes and can influence health outcomes. Identifying and interpreting such variation requires an accurate, valid and representative dataset to firstly define what variants are present and then assess the potential relevance for the health of a person, their family/whānau and the wider community to which they belong. Globally the variation embedded within genomes differs enormously and has been shaped by the size, constitution, historical origins and evolutionary history of their source populations. Māori, and more broadly Pacific peoples, differ substantially in terms of genomic variation compared to the more closely studied European and Asian populations. In the absence of accurate genomic information from Māori and Pacific populations, the precise interpretation of genomic data and the success and benefits of genomic medicine will be disproportionately less for those Māori and Pacific peoples. In this viewpoint article we, as a group of healthcare professionals, researchers and scientists, present a case for assembling genomic resources that catalogue the characteristics of the genomes of New Zealanders, with an emphasis on peoples of Māori and Polynesian ancestry, as a healthcare imperative. In proposing the creation of these resources, we note that their governance and management must be led by iwi and Māori and Pacific representatives. Assembling a genomic resource must be informed by cultural concepts and values most especially understanding that, at a physical and spiritual level, whakapapa is embodied within the DNA of a person. Therefore DNA and genomic data that connects to whakapapa (genealogy) is considered a taonga (something precious and significant), and its storage, utilisation and interpretation is a culturally significant activity. Furthermore, such resources are not proposed to primarily enable comparisons between those with Māori and broader Pacific ancestries and other Aotearoa peoples but to place an understanding of the genetic contributors to their health outcomes in a valid context. Ongoing oversight and governance of such taonga by Māori and Pacific representatives will maximise hauora (health) while also minimising the risk of misuse of this information.

[1]  J T Hart,et al.  THE INVERSE CARE LAW , 1971 .

[2]  Anthony E. Reeve,et al.  E-cadherin germline mutations in familial gastric cancer , 1998, Nature.

[3]  T Ishizaki,et al.  High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. , 1999, Pharmacogenetics.

[4]  Charles E. Schwartz,et al.  Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans , 2003, Nature Genetics.

[5]  A. Sporle,et al.  Genetics, race, ethnicity, and health , 2004, BMJ : British Medical Journal.

[6]  J. Champagne,et al.  Nav1.5/R1193Q polymorphism is associated with both long QT and Brugada syndromes. , 2006, The Canadian journal of cardiology.

[7]  Rod A Lea,et al.  Monoamine oxidase, addiction, and the "warrior" gene hypothesis. , 2007, The New Zealand medical journal.

[8]  I. Winship,et al.  Cultural enhancement of a clinical service to meet the needs of indigenous people; genetic service development in response to issues for New Zealand Maori , 2007, Clinical genetics.

[9]  M. King,et al.  Scientific responsibility for the dissemination and interpretation of genetic research: lessons from the “warrior gene” controversy , 2008, Journal of Medical Ethics.

[10]  Bruce G. Link,et al.  Medical Advances and Racial/Ethnic Disparities in Cancer Survival , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[11]  M. Guyer,et al.  Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.

[12]  Xingyu,et al.  The Effect of Chromosome 9 p 21 Variants on Cardiovascular Disease May Be Modified by Dietary Intake : Evidence from a Case / Control and a Prospective Study , 2011 .

[13]  M. Benton,et al.  Complete Mitochondrial Genome Sequencing Reveals Novel Haplotypes in a Polynesian Population , 2012, PloS one.

[14]  R. Lea,et al.  HLA and MICA polymorphism in Polynesians and New Zealand Maori: implications for ancestry and health. , 2013, Human immunology.

[15]  T. Sammour,et al.  Cancer in Māori: lessons from prostate, colorectal and gastric cancer and progress in hereditary stomach cancer in New Zealand , 2013, ANZ journal of surgery.

[16]  E. Matisoo-Smith,et al.  Hyperuricaemia in the Pacific: why the elevated serum urate levels? , 2014, Rheumatology International.

[17]  J. Hindmarsh,et al.  Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption , 2013, Arthritis Research & Therapy.

[18]  T. Merriman,et al.  Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load , 2013, Annals of the rheumatic diseases.

[19]  Ajay K. Royyuru,et al.  Geographic population structure analysis of worldwide human populations infers their biogeographical origins , 2014, Nature Communications.

[20]  G. Shipley,et al.  Genetic structure among Fijian island populations , 2015, Journal of Human Genetics.

[21]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[22]  D. Goldstein,et al.  Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine , 2016, Genome Biology.

[23]  J. Skinner,et al.  A Prospective Study of Sudden Cardiac Death among Children and Young Adults. , 2016, The New England journal of medicine.

[24]  D. Weeks,et al.  A thrifty variant in CREBRF strongly influences body mass index in Samoans , 2016, Nature Genetics.

[25]  James Y. Zou Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[26]  Peter Szolovits,et al.  Genetic Misdiagnoses and the Potential for Health Disparities. , 2016, The New England journal of medicine.

[27]  Zachary A. Szpiech,et al.  Challenges and disparities in the application of personalized genomic medicine to populations with African ancestry , 2016, Nature Communications.

[28]  E. Ashley Towards precision medicine , 2016, Nature Reviews Genetics.

[29]  E. Burchard,et al.  Towards Equity in Health: Researchers Take Stock , 2016, PLoS medicine.

[30]  Jonathan Scott Friedlaender,et al.  Excavating Neandertal and Denisovan DNA from the genomes of Melanesian individuals , 2016, Science.

[31]  Dermot F. Reilly,et al.  Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting , 2017, Circulation.

[32]  J. Hindmarsh,et al.  Population‐Specific Resequencing Associates the ATP‐Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men , 2017, Arthritis & rheumatology.

[33]  M. Hudson,et al.  Engaging Māori in biobanking and genomic research: a model for biobanks to guide culturally informed governance, operational, and community engagement activities , 2016, Genetics in Medicine.

[34]  W. Burke,et al.  P450 Pharmacogenetics in Indigenous North American Populations , 2018, Journal of personalized medicine.